Zacks.com on MSN2h
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ DrugsThis week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...
Kajeet and Avery Telehealth announced a strategic partnership. The FDA has approved Apple’s sleep apnea detection feature.
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...
The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce ...
The FDA has expanded its approval of Kisqali, a drug already approved to treat advanced breast cancer, to include women with ...
2don MSN
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...
Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...
The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic therapies and Bain is funding a growing CDMO.
The FDA has approved Kisqali (ribociclib) in adults with HR-positive, HER2-negative stage II and III early breast cancer.
Novartis says it's not interested in joining weight-loss drugs frenzy. CEO Vas Narasimhan explained why today on CNBC's "Squawk Box Europe".
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback